Phase I open-label trial evaluating BI 1810631 as monotherapy in the treatment of patients with advanced or metastatic solid tumors with HER2 aberrations (BEAMION-Lung 1)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Her2 Mutation-positive Nsclc
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic non-haematologic malignancy
    2. Availability and patient willingness to provide a sample of tumour for confirmation of the patient┬┤s

You may not be eligible for this study if the following are true:

    1. Major surgery performed within 4 weeks prior to first trial treatment or planned within 6 months after screening
    2. Treatment with a systemic anti-cancer therapy or investigational drug within 21 days of the first treatment

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.